ASCO Annual Meeting | Conference

Dr. Ramalingam on Avelumab Plus Lorlatinib in NSCLC

June 23rd 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the combination of avelumab (Bavencio) plus lorlatinib in patients with non–small cell lung cancer.

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

June 23rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the rationale for the IMvigor130 study in metastatic bladder cancer.

Dr. Richardson Discusses the Results of the OPTIMISMM Trial in Myeloma

June 23rd 2018

Paul Richardson, MD, clinical program leader, director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the results of the OPTIMISMM trial in patients with multiple myeloma.

Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple Myeloma

June 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the role of stem cell transplant in patients with multiple myeloma.

Dr. Ascierto on the COLUMBUS Trial in Melanoma

June 21st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.

Dr. Kolberg Discusses the Central Pathology Review of ABP 980

June 21st 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the central pathology review of the trastuzumab (Herceptin) biosimilar ABP 980.

Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC

June 20th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Zibelman on Managing Immune-Related Adverse Events

June 16th 2018

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).

Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC

June 14th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer.

Dr. Drake Discusses the CARMENA Trial in Metastatic RCC

June 14th 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Dr. McBride Discusses Financial Toxicity in Oncology

June 14th 2018

Ali McBride, PharmD, MS, BCOP, Clinical Coordinator of Hematology/Oncology, The University of Arizona Cancer Center, and President-Elect of the Association of Community Cancer Centers.

Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

June 14th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC

June 14th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.

Dr. Tewari on Trial With Cemiplimab in Recurrent or Metastatic Cervical Cancer

June 14th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the GOG 3016/ENGOT-cx9 trial in patients with recurrent or metastatic cervical cancer.

Dr. Wang Discusses the ZUMA-2 Trial in Mantle Cell Lymphoma

June 12th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.

Dr. O'Malley on the FORWARD II Phase Ib Study in Ovarian Cancer

June 12th 2018

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses the safety and efficacy results of the FORWARD II phase Ib study in patients with ovarian cancer.

Dr. Dent Discusses the LOTUS Trial in Triple-Negative Breast Cancer

June 12th 2018

Rebecca Dent, MD, senior consultant, National Cancer Center, Singapore, discusses the results of the LOTUS trial in patients with triple-negative breast cancer.

Dr. Flaherty Discusses the COLUMBUS Trial in Melanoma

June 12th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the COLUMBUS trial in patients with BRAF-mutant melanoma.

Dr. Rini Discusses the Findings of IMmotion151 in RCC

June 12th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses findings from the IMmotion151 trial in renal cell carcinoma.

Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL

June 12th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.